Literature DB >> 33171054

Macular Corneal Dystrophy: An Updated Review.

Shalini Singh1, Sujata Das2, Chitra Kannabiran3, Saumya Jakati4, Sunita Chaurasia1.   

Abstract

Macular Corneal Dystrophy is an autosomal recessive form of corneal dystrophy due to a mutation in CHST6 gene, which results in abnormal proteoglycan synthesis. There is accumulation of abnormal glycosaminoglycans in the corneal stroma and endothelium. The deposition results in progressive loss of corneal transparency and visual acuity. The histopathology shows characteristic alcian blue positive deposits. Management in the cases with visual loss requires keratoplasty either full thickness or lamellar. The decision about the ideal type of keratoplasty depends on age and pre-operative clinical features. Although prognosis after keratoplasty is good, recurrences can occur. Future research should be targeted towards gene therapy in this condition.

Entities:  

Keywords:  CHST6; Macular corneal dystrophy; genetics; glycosaminoglycans; keratoplasty

Mesh:

Substances:

Year:  2020        PMID: 33171054     DOI: 10.1080/02713683.2020.1849727

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  3 in total

Review 1.  Roles and Mechanisms of Regulated Necrosis in Corneal Diseases: Progress and Perspectives.

Authors:  Wanying Lin; Minting Chen; Yacouba Cissé; Xiaofeng Chen; Lang Bai
Journal:  J Ophthalmol       Date:  2022-05-23       Impact factor: 1.974

2.  Novel compound heterozygous mutations in the CHST6 gene cause macular corneal dystrophy in a Han Chinese family.

Authors:  Yanxia Huang; Lamei Yuan; Yanna Cao; Renhong Tang; Hongbo Xu; Ziqian Tang; Hao Deng
Journal:  Ann Transl Med       Date:  2021-04

3.  Histological findings of corneal tissue after failed phototherapeutic keratectomy in macular corneal dystrophy - a case report.

Authors:  Caroline Julia Gassel; Jens Martin Rohrbach; Daniel Röck; Karl Ulrich Bartz-Schmidt; Tobias Röck
Journal:  BMC Ophthalmol       Date:  2022-05-08       Impact factor: 2.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.